Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment
- Conditions
- First Posted Date
- 2003-07-30
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 77
- Registration Number
- NCT00014209
- Locations
- 🇨🇦
Credit Valley Hospital, Mississauga, Ontario, Canada
🇨🇦Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
- Conditions
- First Posted Date
- 2003-07-24
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- The Christie NHS Foundation Trust
- Registration Number
- NCT00004887
- Locations
- 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 94
- Registration Number
- NCT00003211
- Locations
- 🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States
🇦🇺Royal Children's Hospital, Parkville, Victoria, Australia
🇦🇺Children's Hospital at Westmead, Westmead, New South Wales, Australia
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
- Conditions
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 513
- Registration Number
- NCT00064077
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- GOG Foundation
- Target Recruit Count
- 1381
- Registration Number
- NCT00063999
- Locations
- 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Greater Baltimore Medical Center, Baltimore, Maryland, United States
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
- Conditions
- Adenocarcinoma of the EsophagusMixed Adenocarcinoma of the StomachRecurrent Esophageal CancerStage IIIA Gastric CancerStage IV Esophageal CancerAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachRecurrent Gastric CancerSquamous Cell Carcinoma of the EsophagusStage III Esophageal Cancer
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00064259
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Combination Chemotherapy in Treating Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2003-06-20
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Registration Number
- NCT00024323
- Locations
- 🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)
- Conditions
- First Posted Date
- 2003-06-17
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- American College of Radiology Imaging Network
- Registration Number
- NCT00023868
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Combination Chemotherapy in Treating Patients With Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-06-10
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 42
- Registration Number
- NCT00014534
- Locations
- 🇺🇸
Geisinger Medical Group, State College, Pennsylvania, United States
🇺🇸William N. Wishard Memorial Hospital, Indianapolis, Indiana, United States
🇺🇸Rebecca and John Moores UCSD Cancer Center, San Diego, California, United States
Combination Chemotherapy in Treating Patients With Solid Tumors
- Conditions
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.